Health Care Sector Update For 01/30/2015: Icpt,qtnt,dndnq, Vrx – Nasdaq.com

address

Health Care Sector Update for 01/30/2015: ONCE,QTNT,DNDN – NASDAQ.com

Drugs qualifying for breakthrough designation by the U.S. Food and Drug Administration typically must show substantial improvement on a clinically significant endpoint compared with other currently available therapies. The company submitted efficacy and safety data from a pair of placebo-controlled Phase II trials, including testing of obeticholic acid in 64 patients with nonalcoholic steatohepatitis to measure its impact on insulin sensitivity. Another trial involving 283 participants sought to measure the drug’s efficacy on liver histology and fibrosis. ICPT shares were up more than 21% at $207.33 apiece, easing from an earlier session high at $210.00 a share. The stock has traded within a 52-week range of $128.50 to $484.99 a share, slipping more than 42% over the past 12 months. In other sector news, (+) QTNT, (+22.4%) Forms exclusive commercial partnership with Ortho clinical Diagnostics to market its MosaiQ test platform for the global transfusion diagnostics markets. (-) DNDNQ, (-13.6%) Receives $296 mln “stalking-horse” bid for world-wide rights for its Provenge cancer vaccine from Valeant Pharmaceuticals ( VRX ). The bankrupt company extended deadline for additonal bids through Feb. 10.
Health Care Sector Update for 01/30/2015: ICPT,QTNT,DNDNQ, VRX – NASDAQ.com

https://www.youtube.com/v/6LN2QDaQr38

In health-care stocks news, Johnson & Johnson ( JNJ ) announced that the U.S. Food and Drug Administration (FDA) approved its Janssen unit’s combination tablet Prezcobix (darunavir 800 mg/cobicistat 150 mg) tablets, an HIV-1 protease inhibitor combined with a CYP3A4 inhibitor, for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral agents for treatment-naive and treatment-experienced adults with no darunavir resistance-associated substitutions. Over the past 52 weeks, the company has traded between $86.09 and $109.49 Meanwhile Epirus Biopharmaceuticals ( EPRS ), a developer of biosimilar monoclonal antibodies, said it has priced an underwritten public offering of 9.6 million shares at $5.00 each or a 7% discount to Thursday’s closing price. Over the past 52 weeks, the company has traded between $3.78 and $17.40. And Oxford Immunotec Global ( OXFD ) said it has priced an underwritten offering of $4.26 million shares at $11.75 each, or a 1.5% discount to yesterday’s closing price. The company was trading 1.0% higher at $12.05 during pre-market trading. Over the past 52 weeks, the company has traded between $10.01 and $25.38. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc. Copyright (C) 2014 MTNewswires.com.
http://www.nasdaq.com/article/health-care-sector-update-for-01302015-jnj-eprs-oxfd-cm438399

Health Care Sector Update for 01/30/2015: JNJ, EPRS, OXFD – NASDAQ.com

In company news, Spark Therapeutics ( ONCE ) surged in its first day as a pubic company after the gene-therapy company priced an initial public offering of 7 million shares of its common stock at $23 apiece, topping its expected range by $2 a share and raising $161 million in gross proceeds. The company develops gene therapy treatments targeting rare blinding conditions, hematologic disorders and neurodegenerative diseases. It said the IPO proceeds will fund research and development of its SPK-RPE65, SPK-CHM and SPK drug candidates. ONCE shares were ahead more than 117% at $50.06 apiece shortly before the closing bell, reaching a new high for the session. In other sector news, (+) QTNT, Forms exclusive commercial partnership with Ortho clinical Diagnostics to market its MosaiQ test platform for the global transfusion diagnostics markets. (-) DNDN, Receives $296 mln “stalking-horse” bid for world-wide rights for its Provenge cancer vaccine from Valeant Pharmaceuticals (VRX,VRX.TO). The bankrupt company extends deadline for additional bids through Feb. 10. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.
Health Care Sector Update for 01/30/2015: ONCE,QTNT,DNDN – NASDAQ.com

Advertisements